Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label Study of PRAX-944 to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Escalating Multiple Oral Doses in Adults with Generalized Epileptic Syndromes with Absence Seizures

Trial Profile

A Phase 2, Open-label Study of PRAX-944 to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Escalating Multiple Oral Doses in Adults with Generalized Epileptic Syndromes with Absence Seizures

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2018

At a glance

  • Drugs PRAX-944 (Primary)
  • Indications Generalised epilepsy
  • Focus Adverse reactions
  • Sponsors Praxis Precision Medicines
  • Most Recent Events

    • 23 Aug 2018 Planned initiation date changed from 16 Jul 2018 to 17 Sep 2018.
    • 13 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top